Mackenzie Financial
ARQT icon

Mackenzie Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Mackenzie Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$756K Sell
28,837
-59,424
-67% -$1.38M ﹤0.01% 1234
2026
Q1 		$2.08M Buy
88,261
+39,236
+80% +$1M ﹤0.01% 918
2025
Q4 		$1.37M Buy
+49,025
New +$1.26M ﹤0.01% 969

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mackenzie Financial's ARQT Position: Q2 2026 in Review

Mackenzie Financial reduced its Arcutis Biotherapeutics (ARQT) stake by 67% in Q2 2026, selling an estimated $1.38M and leaving 28,837 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #1234.

Mackenzie Financial first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.08M in Q1 2026. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Mackenzie Financial held 28,837 shares of Arcutis Biotherapeutics worth $756K as of Q2 2026.
  • Mackenzie Financial sold 59,424 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.38M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1234 holding.
  • Mackenzie Financial first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mackenzie Financial's Arcutis Biotherapeutics position peaked at $2.08M in Q1 2026.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.